Working group report of hypertension in pregnancy. J Clin Hypertens 2001 Mar-Apr;3(2):75-88.
Diagnosis management and evaluation of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 2014 May;36(5):416-441.
Subsequent pregnancy outcome in women with a history of HELLP syndrome at less than or at 28 weeks of gestation. Am J Obstet Gynecol 2003 Jun;188(6):1504-1507.
Hypertension; a companion to Braunwald's heart diseases. 3rd ed. Elsevier; 2013. pp. 361-372.
The natural history of white coat hypertension in pregnancy. BJOG 2005 May;112(5):601-606.
Intracerebral hemorrhage a life threatening complication of hypertension in pregnancy. J Clin Hypertens 2007 Nov;9(11):897-900.
Chronic hypertension in pregnancy and the risk of congenital malformations, a cohort study. Am J Obstet Gynecol 2015 Mar;212(3):337.
Report of the American College of Obstetricians and Gynecologists (ACOG) Task force on hypertension in pregnancy. Obstet Gynecol 2016;127:e52-e53.
Preeclampsia rates in United States 1980-2010: age-period-cohort analysis. BMJ 2013;347:f6564.
Risk of preeclampsia in first and subsequent pregnancies: prospective cohort study. BMJ 2009 Jun;338:b2255.
Plasma concentration of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One 2012;7(10):e48259.
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006 Sep;355(110):992-1005.
Predictive value of the sFlt-1:PlGF ratio in women with suspected PE. N Engl J Med 2016 Jan;374(1):13-22.
ESC guidelines on the management of cardiovascular diseases during pregnancy of the European society of cardiology (ESC). Eur Heart J 2011 Dec;32(24):3147-3197.
Stroke and severe preeclampsia and eclampsia, a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005 Feb;105(2):246-254.
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006 Jun;12(7):642-649.
